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This study aimed to identify the optimal dose of the endothelin-1 receptor antagonist atrasen-
tan with maximal albuminuria reduction and minimal signs of sodium retention, as manifested by
increase in bodyweight. Data from the RADAR-JAPAN studies were used, evaluating the effect
of 0.75 or 1.25 mg/d of atrasentan in 161 patients with type 2 diabetes and kidney disease.
Individual pharmacokinetic parameters were estimated using a population pharmacokinetic
approach. Subsequently, changes in the urinary albumin-to-creatinine ratio (UACR) and body-
weight from baseline after 2 weeks' exposure were modelled as a function of the pharmacoki-
netic parameters. The 0.75 and 1.25 mg doses showed a mean UACR reduction of 34.0% and
40.1%, whereas mean bodyweight increased by 0.9 and 1.1 kg, respectively. A large variation
between individuals was observed in the UACR and bodyweight responses. Individual pharma-
cokinetic parameters correlated significantly with both individual UACR and bodyweight
responses (P < .01). The individual response curves for UACR and bodyweight crossed at
approximately the mean trough concentration of 0.75 mg atrasentan, indicating that 0.75 mg/d
of atrasentan is the optimal dose for kidney protection with maximal efficacy (albuminuria
reduction) and safety (minimal sodium retention).
KEYWORDS
diabetic nephropathy, dose-finding, endothelin receptor antagonist, pharmacodynamics,
pharmacokinetics
1 | INTRODUCTION
Defining the dose of a drug with optimal efficacy and safety is impor-
tant for a drug's development programme and its use in clinical prac-
tice. This is especially important for drugs with a narrow therapeutic
window, or drugs for which the efficacy and safety exposure-response
curves overlap.
Endothelin receptor antagonists (ERAs) are an example of a
class of drugs with a narrow therapeutic window. The class is
tested for cardiovascular protection, including reducing the progres-
sion of kidney disease.1–4 Albuminuria lowering is believed to be an
efficacy biomarker that reflects the drug's efficacy to delay
progression of kidney disease, whereas the sodium retention during
endothelin receptor antagonism is a biomarker for unwanted side
effects. The optimal dose of an ERA for kidney protection is a bal-
ance between maximal albuminuria lowering and minimal sodium
retention.
Atrasentan is an ERA that has been shown to decrease albumin-
uria at relatively low doses of 0.75 and 1.25 mg/d in the dose-finding
phase 2 RADAR trial.5 However, even at these low doses, atrasentan
also caused sodium retention as manifested by increases in body-
weight. The aim of this study is to employ exposure-response analyses
to identify the optimal atrasentan dose with maximal albuminuria
reduction and minimal sodium retention.
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2 | METHODS
2.1 | Clinical trial design and patient population
Data from 161 participants in the RADAR (NCT01356849) and
JAPAN (NCT01424319) trials were used. The RADAR and JAPAN tri-
als assessed the effect of atrasentan on albuminuria reduction. The
design and primary results of both trials were previously published.5
To be eligible, participants were required to have a urinary albumin-
to-creatinine ratio (UACR) within 300 to 3500 mg/g and an estimated
glomerular filtration rate (eGFR) of 30 to 75 mL/min/1.73 m2. As per
protocol, all participants received the maximum tolerated labeled daily
dose of a renin-angiotensin-aldosterone-system (RAAS) inhibitor.
Patients were randomly allocated to 12 weeks of treatment with atra-
sentan at doses of 0.75 or 1.25 mg/d, or a placebo using a double-
blind design. The primary endpoint of the trial was the change in
UACR over time.
Three consecutive first-void urine specimens were collected at
baseline and every 2 weeks thereafter to determine urinary albumin
and creatinine concentrations. Blood samples were sparsely collected
to determine plasma atrasentan exposure. In line with previous
reports of this trial, changes in bodyweight were used as proxy for
sodium retention. Analyses focused on changes in sodium retention
after 2 weeks of atrasentan therapy in order to maximise detection of
atrasentan on sodium retention.
2.2 | Pharmacokinetic and pharmacodynamic
analyses
The population pharmacokinetic model was previously published.6
The original data file and model results were combined to generate a
simulation dataset (data transformations and visualisations were per-
formed in R3.4.2 [R Foundation for Statistical Computing, Vienna,
Austria]). For each individual, the simulation dataset contained dosing
information, demographics and post-hoc Bayesian pharmacokinetic
parameter estimates (e.g. individual absorption rates, clearances and
volumes of distribution). For simulation purposes, all available phar-
macokinetic observations were set at missing. In order to obtain addi-
tional individual pharmacokinetic parameters (e.g. area-under-the-
plasma-concentration time curve [AUC]), atrasentan exposure was
simulated on day 14 after first dosing in time steps of 0.1 hour. Simu-
lations were run in NONMEM 7.3 (ICON Development Solutions,
Ellicott City, MD, USA) using the individual post-hoc Bayesian param-
eter estimates and the original model structure. The simulated phar-
macokinetic profiles per individual were used to obtain the following
individual pharmacokinetic parameters on day 14: maximum plasma
atrasentan concentration (Cmax), trough concentration (Ctrough [on
day 15]), and average steady state concentration (Css). The individual
AUC for day 14 (AUCd14) was calculated by the amount of adminis-
tered/individual clearance. Subsequently, regression analyses were
performed to assess the association between the change from base-
line in log-transformed UACR and bodyweight after 2 weeks with
Ctrough, Cmax, Css and AUC d14.
3 | RESULTS
Baseline characteristics of patients assigned to 0.75 and 1.25 mg doses
of atrasentan were reported previously.5 The mean Ctrough (2.5th to
97.5th Percentile [P]) of atrasentan at week 2 was 1.7 ng/mL (0.4-4.7)
and 3.4 ng/mL (1.0-10.0) for the 0.75 and 1.25 mg doses, respectively.
After 2 weeks of treatment with either 0.75 or 1.25 mg of atrasentan,
UACR decreased by 34.0% (P < .01) and 40.1% (P < .01), respectively,
compared to baseline, with a large variation among individuals (2.5th to
97.5th P: −68.4 to 70.5 and −76.2 to 12.3). The mean increase in body-
weight [2.5th to 97.5th P] with 0.75 and 1.25 mg of atrasentan was
0.9 kg [−1.0 to 3.0] and 1.1 kg [−1.0 to 4.0], respectively. The individu-
ally predicted values for Ctrough, Css, Cmax and AUCd14 correlated signifi-
cantly to both individual UACR and bodyweight responses (Table 1).
Figure 1 shows that the exposure-response curves for albuminuria and
bodyweight crossed at a mean Ctrough corresponding to approximately
0.75 mg of atrasentan per day. At the mean Ctrough of the 1.25 mg
dose, a slightly larger albuminuria response was observed, at the
expense of a larger increase in bodyweight probably because of a larger
degree of sodium retention. Results were similar when Css, Cmax and
AUCd14 were modelled (Figure S1).
4 | DISCUSSION
This study showed a large individual variation in albuminuria and
sodium retention (bodyweight) response after 2 weeks of treatment
with a low dose of atrasentan. The observed variation in albuminuria
and bodyweight response correlated to the variation in the estimated
individual pharmacokinetic parameters of atrasentan. At the atrasen-
tan Ctrough equivalent to the administration of 0.75 mg of atrasentan,
a significant and clinically relevant reduction in albuminuria was
observed with fewer signs of sodium retention in comparison to a
Ctrough equivalent to the administration of 1.25 mg of atrasentan.
Regulatory agencies have developed rigorous guidelines on how
to use dose-response data to support dose selection and drug regis-
tration.7,8 Despite these rigorous guidelines, dose-finding studies to
determine the optimal therapeutic dose are hampered by various
TABLE 1 Associations between pharmacokinetic parameters and albuminuria and bodyweight response at 2 weeks
Mean (95% CI) % change in UACR per
2-fold increase in atrasentan concentration P
Mean (95% CI) change in bodyweight in kg per
2-fold increase in atrasentan concentration P
Ctrough −9.8 (−15.7 to −3.5) .003 0.31 (0.10-0.52) .004
Css −10.2 (−16.3 to −3.6) .003 0.30 (0.08-0.52) .008
Cmax −10.3 (−16.6 to −3.5) .004 0.28 (0.05-0.51) .019
24-hour AUCd14 −9.9 (−16.1 to −3.3) .004 0.30 (0.08-0.52) .008
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factors. Firstly, dose-finding studies often include only a small number
of patients per drug-dose arm. Combined with the consideration that
the individual exposure and response to many drugs vary substantially
among patients,9 the small sample size compromises accurate and pre-
cise determination of the optimal dose. Secondly, the patient popula-
tion included in the dose-finding studies is not always representative
of the population enrolled in confirmatory clinical trials and those who
will eventually be treated in clinical practice; this is because the latter
population is often more heterogeneous with varying degrees of renal
or hepatic function, multiple comorbidities, and the use of many con-
comitant medications. Each of these factors can alter dose-exposure-
response relationships.
A further problem in determining the optimal therapeutic dose is
that its selection is based on an inadequate balance between efficacy
and safety. Traditionally, dose finding is based on the drug's efficacy
in modifying a single risk factor that the drug is targeting—for exam-
ple, blood pressure for an antihypertensive drug. The safety is mainly
established from a fixed set of parameters. However, many drugs have
effects on other parameters (off-target effects), which may also be risk
factors that contribute to clinical outcomes, either in a positive or a
negative way. The sodium retention effect of ERAs is one such off-
target effect that contributes to clinical outcomes in a negative way.
Therefore, dose selection should be based on the balance of drug
effects on multiple parameters, both on those that contribute to pro-
tection and those that induce harm.
These problems in selecting the optimal therapeutic dose for an
ERA are illustrated by the ERA avosentan. A phase III trial (ASCEND)
with avosentan was terminated early because of an increased inci-
dence of congestive heart failure probably caused by the sodium-
retaining effects.10 In hindsight, the increased sodium retention and
congestive heart failure could have been expected, because the high
doses of 25 and 50 mg used in the phase III trial were associated with
significant sodium retention and peripheral edema in an earlier dose-
finding trial.11 Despite the high incidence of edema, the 25 and 50 mg
doses were selected for the phase III outcome trial. This highlights the
importance of careful dose selection when balancing maximal albu-
minuria reduction and minimal sodium retention.
Additionally, the high doses used in the ASCEND trial are not the
only explanation for the increased edema and heart failure, but also
the difference in populations studied in the phase III outcome trial and
the dose-finding study. In the phase III trial, patients with overt dia-
betic nephropathy were enrolled; they had a mean eGFR of 33 mL/
min/1.73 m2.3 These patients are prone to sodium retention. How-
ever, in the dose-finding study, patients who are less prone to sodium
retention, with an estimated creatinine clearance of ~80 mL/min,
were enrolled.12 This finding also highlights the importance of strictly
monitoring patients with diabetes and impaired kidney function for
signs of sodium retention.
For the development of the ERA atrasentan, the main inclusion
and exclusion criteria for the phase II and III trials were kept similar,
and the sodium-retaining effects of atrasentan were carefully analysed
during the dose selection process. However, the sample size of the
atrasentan phase II dose-finding study was small, thus limiting the
accuracy and precision of the dose-finding analyses.
In conclusion, the exposure-response analysis showed that
0.75 mg/d of atrasentan as an adjunct to RAAS inhibition is the opti-
mal dose for renal protection with maximal albuminuria reduction
while minimising sodium retention.
FIGURE 1 Predicted atrasentan trough
concentration versus predicted albuminuria
(green) and predicted bodyweight response
(red). The mean predicted response (solid
line) is shown for the 95% prediction
intervals (shaded areas). The dotted lines
represent the mean atrasentan trough
concentrations for 0.75 and 1.25 mg doses
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